Intersect ENT, Inc. (NASDAQ:XENT) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
(e)
2017 Salary Increases, Option Grants and Bonus Plan
for Named Executive Officers
On January18, 2017, the Compensation Committee of the Board of
Directors (the Compensation Committee) of Intersect ENT, Inc.
(the Company) approved annual salaries, stock option awards,
restricted stock units and target bonus percentages for 2017 for
the Companys Chief Executive Officer, Chief Financial Officer,
Chief Operating Officer and Vice President of Clinical Affairs,
each a Named Executive Officer (as defined under applicable
securities laws). The 2017 compensation information for such
executive officers is set forth on Exhibit 10.1 to this Current
Report on Form 8-K, which is incorporated herein by reference.
The Compensation Committee also approved the form of restricted
stock unit award agreement, a copy of which is filed hereto as
Exhibit 10.2. All restricted stock unit awards granted by the
company shall be subject to the terms and conditions
substantially in the form set forth in thisform of restricted
stock unit award agreement.
| Item9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
|
ExhibitNo. |
Description |
|
| 10.1 | 2017 Named Executive Officer Compensation. | |
| 10.2 |
Form of Restricted Stock Unit Award Agreement under the 2014 Equity Incentive Plan. |
About Intersect ENT, Inc. (NASDAQ:XENT)
Intersect ENT, Inc. is a commercial stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. It has developed a drug releasing bio-absorbable implant technology that enables targeted and sustained release of therapeutic agents. Its commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. It is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. Its steroid releasing implants are the drug releasing implants for chronic sinusitis sufferers. The PROPEL mini implant is a smaller version of PROPEL and is manufactured from the same bio-absorbable polymer fiber and with the same drug releasing coating and other design characteristics. It also developing NOVA, a steroid releasing implant. Intersect ENT, Inc. (NASDAQ:XENT) Recent Trading Information
Intersect ENT, Inc. (NASDAQ:XENT) closed its last trading session down -0.15 at 12.45 with 192,577 shares trading hands.
